Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIXOPHYLLIN vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal elimination half-life in adults is approximately 7-9 hours (range 3-12 hours) for non-smokers, and 4-5 hours for smokers. In children (1-9 years), half-life averages 3-4 hours; in neonates, it is prolonged (20-30 hours). Clinical context: Half-life may be increased in hepatic impairment, congestive heart failure, and with concurrent administration of drugs that inhibit CYP1A2 and CYP3A4 (e.g., cimetidine, erythromycin, ciprofloxacin). Decreased half-life occurs with enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, smoking).
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Theophylline is primarily eliminated by hepatic metabolism (approximately 90%), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug accounts for about 10% in adults, but in neonates and infants, it may be higher (up to 50%). Fecal excretion is negligible (<1%).
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Approximately 40-60% bound to plasma proteins, primarily albumin. Binding is saturable and may decrease in uremia or with elevated bilirubin. In neonates, protein binding is lower (about 20-30%) due to decreased albumin concentrations.
85-90% bound to albumin.
Volume of distribution: approximately 0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Theophylline distributes into total body water, with some accumulation in tissues. Vd is increased in neonates (0.6-0.9 L/kg) and decreased in obesity (0.3-0.4 L/kg adjusted for ideal body weight).
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 90-100% (well absorbed). Oral extended-release: 80-100% (inter- and intra-subject variability exists). Rectal solution: 80-90%. Rectal suppository: 60-70% (erratic absorption). Intravenous: 100%.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
Theophylline pharmacokinetics are not significantly altered in renal impairment. No dose adjustment recommended for GFR >15 m L/min. For end-stage renal disease (GFR <15 m L/min), monitor serum theophylline concentrations closely as clearance may be reduced; consider 25% dose reduction and follow levels.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class A: Reduce dose by 50% of usual. Child-Pugh Class B: Reduce dose by 50-75% of usual. Child-Pugh Class C: Contraindicated or reduce dose by 80% with close monitoring. Serum theophylline concentration monitoring is mandatory.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Immediate-release: Initial dose 16 mg/kg/day or 400 mg/day (whichever is less) PO divided every 6-8 hours; titrate based on serum theophylline concentration. Typical maintenance: <1 year: 0.2 x age in weeks + 5 mg/kg/day; 1-9 years: 24 mg/kg/day; >9 years: 16 mg/kg/day. Maximum dose 800 mg/day.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Elderly patients (>60 years) have reduced theophylline clearance. Initial dose 300 mg/day PO divided every 8-12 hours; maximum recommended dose 400 mg/day. Monitor serum theophylline concentrations closely and adjust to avoid levels >15 mcg/m L due to increased risk of toxicity.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA black box warning.
No FDA boxed warning exists for this combination product.
Monitor serum theophylline levels due to narrow therapeutic index; risk of toxicity with levels >20 mcg/m L. Use caution in patients with cardiac disorders, hepatic impairment, elderly, and those on medications that alter theophylline metabolism.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline or any component of the formulation; peptic ulcer disease; seizure disorder (unless adequately controlled).
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid high-caffeine foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. Dietary protein and charcoal-broiled meats may increase clearance, potentially reducing efficacy. Consistency in diet is recommended.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limited; may be associated with intrauterine growth restriction and neonatal withdrawal if used near term. Second trimester: Risk of tachyarrhythmias and fetal hypoxia due to maternal toxicity. Third trimester: Increased risk of neonatal apnea, jitteriness, and irritability due to transplacental passage. Avoid use unless clearly needed.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Peak milk levels occur 2-4 hours after dose. Infant serum levels are typically low (10-30% of maternal levels). Risk of irritability and jitteriness in infants. Use with caution; monitor infant for adverse effects.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Due to increased clearance of theophylline in pregnancy (by up to 30-50%), dose adjustments are often required. The half-life may decrease significantly, especially in the second and third trimesters. Consider starting with higher doses or more frequent intervals (e.g., every 6-8 hours). Monitor serum concentrations every 2-4 weeks and adjust to maintain therapeutic levels. Postpartum, clearance may decrease, requiring dose reduction.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
ELIXOPHYLLIN is a brand name for theophylline elixir. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Levels >20 mcg/m L increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or COPD. Adjust dose based on smoking status (smokers require higher doses). Drug interactions: cimetidine, ciprofloxacin, fluvoxamine increase levels; phenytoin, carbamazepine, rifampin decrease levels.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, diarrhea, headache, insomnia, irritability, rapid heartbeat, or seizures.,Do not crush or chew extended-release tablets; take elixir with a measuring device for accurate dose.,Notify your doctor if you start or stop smoking, as tobacco use affects how this drug works.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIXOPHYLLIN vs ACCURBRON, answered by our medical review team.
ELIXOPHYLLIN is a Xanthine Bronchodilator that works by Inhibits phosphodiesterase, increasing intracellular c AMP, leading to bronchodilation and anti-inflammatory effects.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIXOPHYLLIN and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIXOPHYLLIN is: Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/m L). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIXOPHYLLIN and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIXOPHYLLIN is classified as Category C. Pregnancy Category C. First trimester: Studies in animals have shown an increased risk of fetal malformations (e.g., cardiac defects, cleft palate) at high doses. Human data limite. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.